Transcatheter Aortic Valve Replacement With the LOTUS Edge System: Early European Experience.

Armario, Xavier; Rosseel, Liesbeth; Kharbanda, Rajesh; Khogali, Saib; Abdel-Wahab, Mohamed; Van Mieghem, Nicolas M; Tchétché, Didier; Dumonteil, Nicolas; De Backer, Ole; Cotton, James; McGrath, Brian; Balakrishnan, Deepu; Ali, Noman; Farhan, Serdar; Joseph, Jubin; Charbonnier, Gaetan; Okuno, Taishi; McHugh, Fiachra; Hildick-Smith, David; Gilgen, Nicole; ... (2021). Transcatheter Aortic Valve Replacement With the LOTUS Edge System: Early European Experience. JACC. Cardiovascular Interventions, 14(2), pp. 172-181. Elsevier 10.1016/j.jcin.2020.09.044

Text Transcatheter_Aortic_Valve_Replacement_with_the_LOTUS.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) | Request a copy

OBJECTIVES

The aim of this study was to evaluate the short-term safety and efficacy of transcatheter aortic valve replacement (TAVR) with the LOTUS Edge system.

BACKGROUND

The LOTUS Edge system was commercially re-released in April 2019. The authors report the first European experience with this device.

METHODS

A multicenter, single-arm, retrospective registry was initiated to evaluate short-term clinical outcomes. Included cases are the first experience with this device and new implantation technique in Europe. Clinical, echocardiographic, and computed tomographic data were analyzed. Endpoints were defined according to Valve Academic Research Consortium-2 and were site reported.

RESULTS

Between April and November 2019, 286 consecutive patients undergoing TAVR with the LOTUS Edge system at 18 European centers were included. The mean age and Society of Thoracic Surgeons score were 81.2 ± 6.9 years and 5.2 ± 5.4%, respectively. Nearly one-half of all patients (47.9%) were considered to have complex anatomy. Thirty-day major adverse events included death (2.4% [n = 7]) and stroke (3.5% [n = 10]). After TAVR, the mean aortic valve area was 1.9 ± 0.9 cm2, and the mean transvalvular gradient was 11.9 ± 5.7 mm Hg. None or trace paravalvular leak (PVL) occurred in 84.4% and moderate PVL in 2.0%. There were no cases of severe PVL. New permanent pacemaker (PPM) implantation was required in 25.9% among all patients and 30.8% among PPM-naive patients.

CONCLUSIONS

Early experience with the LOTUS Edge system demonstrated satisfactory short-term safety and efficacy, favorable hemodynamic data, and very low rates of PVL in an anatomically complex cohort. New PPM implantation remained high. Further study will evaluate if increasing operator experience with the device and new implantation technique can reduce the incidence of PPM implantation.

Interest & Impact

Downloads

1 since deposited on 21 Jan 2022
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item